|
|
News Breaks | | | | September 28, 2012 | | 08:19 EDT |  | PGNX | Progenics Pharmaceuticals initiates Phase 2 clinical trial of PSMA ADC
Progenics Pharmaceuticals has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells. Phase 1 clinical trial data will be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held November 6-9 in Dublin, Ireland. | |
|
News For PGNX From The Last 14 Days Check below for free stories on PGNX the last two weeks. |
|
|
| May 10, 2013 | | 09:00 EDT |  | PGNX | Progenics rises 20.9%
Progenics is up 20.9%, or 90c, to $5.20 | | | 07:45 EDT |  | PGNX | Progenics reports Q1 EPS (22c), consensus (19c)
 Subscribe for More Information | |
|
|
|
|
|
|
